Curiva
Non-invasive patch for same-day cervical cancer diagnosis.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
* | N/A | - | |
| Total Funding | 000k | ||
Related Content
Curiva is a medical technology company focused on developing less invasive diagnostic solutions for gynecologic cancers. Founded in 2018 by Eydis Lima, the company is headquartered in Chicago, Illinois. The founder's background is in chemical engineering and entrepreneurship, with prior research experience in ovarian cancer at Yale University, which inspired the venture. Lima conceived the idea for Curiva's core product after participating in a healthcare hackathon at Yale.
The company’s flagship product is the diaPatch™, a patent-pending, non-invasive diagnostic patch that uses microneedles to detect high-risk biomarkers for cervical cancer. This technology aims to provide a more accurate and patient-centric alternative to traditional methods like the Pap smear and colposcopy, which can be invasive, cause patient anxiety, and have significant false negative rates. The diaPatch™ is designed to deliver results during the same clinical visit, a process taking about 30 minutes, which contrasts sharply with the multi-week wait times often associated with Pap smear results. Curiva reports a high sensitivity and specificity for its device, which would reduce both false negatives and false positives.
Curiva's business model targets healthcare providers and health systems, aiming to reduce diagnostic costs and improve patient compliance. The product ecosystem includes a companion mobile application, the ELLEApp™, which delivers results to both patients and providers, integrates with electronic health records (EHRs), and helps manage follow-up care. The company's long-term vision is to expand its patch technology to create a diagnostic platform for other women's health issues, including ovarian cancer. Curiva has participated in accelerators such as MassChallenge and the Accelerator for Biosciences Connecticut (ABCT) and has raised $2.02 million in funding.
Keywords: cervical cancer diagnostics, non-invasive patch, microneedle technology, gynecologic oncology, same-day results, femtech, medical device, liquid biopsy, early cancer detection, Pap smear alternative, colposcopy alternative, diaPatch, ELLEApp, Eydis Lima, women's health, diagnostic equipment, biomarker detection, patient-centric care, EHR integration, health-tech